UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020774
Receipt number R000023977
Scientific Title Clinical study of ursodeoxycholic acid to evaluate the efficacy and safety of ursodeoxycholic acid for the prevention of common bile duct stones following successful removal.
Date of disclosure of the study information 2016/01/31
Last modified on 2022/02/04 11:38:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical study of ursodeoxycholic acid to evaluate the efficacy and safety of ursodeoxycholic acid for the prevention of common bile duct stones following successful removal.

Acronym

Study of preventive effect of ursodeoxycholic acid on common bile duct stones.

Scientific Title

Clinical study of ursodeoxycholic acid to evaluate the efficacy and safety of ursodeoxycholic acid for the prevention of common bile duct stones following successful removal.

Scientific Title:Acronym

Study of preventive effect of ursodeoxycholic acid on common bile duct stones.

Region

Japan


Condition

Condition

Common bile duct stones

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the preventive efficacy of ursodeoxycholic acid on the recurrence of common bile duct stones following first successive removal, the patients will be observed for 96 weeks with or without the treatment.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endpoint of the study is the duration until stone recurrence with comparison with untreated groups during 96 weeks of study period.

Key secondary outcomes

The factors regarding stone recurrence will be also investigated.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Daily administration of ursodeoxycholic acid for 96 weeks (1-3 divided dose of approximately 10mg/kg body weight)

Interventions/Control_2

no treatment of ursodeoxycholic acid

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Age: 20 years old or older at the time of informed consent.
2.Complete removal of common bile duct stones by endoscopic papillary treatment, and symptom-free period for more than 3 months.
3.No common bile duct stone was proved by CT scan.

Key exclusion criteria

1.A history of gastrectomy.
2.Current treatment for cancer.
3.Complete obstruction of the biliary tract.
4.Current treatment for fulminant hepatitis. Women who were pregnant or breast-feeding, had signs of pregnancy, or were planning to become pregnant.
5.Alcohol abuse.
6.A history of hypersensitivity to the study drug.
7.Current treatment with another bile acid formulation (e.g., Urso or Chino capsule), cholagogue (e.g., dehydrocholic acid, Supacal, Felviten, and Inchinkoto) , bile acid adsorbent (cholestimide or Questran), or agents under development.
8.Patients who were judged to be ineligible for the study by the investigator for other reasons.

Target sample size

420


Research contact person

Name of lead principal investigator

1st name Keishi
Middle name
Last name Kanno

Organization

Hiroshima University Hospital

Division name

Department of General Internal Medicine

Zip code

734-8551

Address

1-2-3, Kasumi, Minami-ku, Hiroshima, Japan

TEL

082-257-5462

Email

kkanno@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name Keishi
Middle name
Last name Kanno

Organization

Hiroshima University Hospital

Division name

Department of General Internal Medicine

Zip code

734-8551

Address

1-2-3, Kasumi, Minami-ku, Hiroshima, Japan

TEL

082-257-5462

Homepage URL


Email

kkanno@hiroshima-u.ac.jp


Sponsor or person

Institute

Department of General Internal Medicine, Hiroshima University Hospital

Institute

Department

Personal name



Funding Source

Organization

Japan Biliary Association

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hiroshima University Certified Review Board

Address

1-2-3 Kasumi, Minami-ku, HiroshimaCity, Hiroshima

Tel

082-257-1551

Email

iryo-seisaku@office.hiroshima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

藤田保健衛生大学坂文種報徳會病院(愛知県)、東邦大学医療センター大森病院(東京都)、名古屋市立大学病院(愛知県)、千葉大学医学部附属病院(千葉県)、埼玉医科大学国際医療センター(埼玉県)


Other administrative information

Date of disclosure of the study information

2016 Year 01 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 01 Month 14 Day

Date of IRB

2019 Year 02 Month 14 Day

Anticipated trial start date

2016 Year 04 Month 01 Day

Last follow-up date

2022 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 01 Month 28 Day

Last modified on

2022 Year 02 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023977


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name